Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia
Russell Schilder*, Arturo Molina, Nancy Bartlett, Thomas Witzig, Leo Gordon, James Murray, Stewart Spies, Hua Wang, Gregory Wiseman, Christine White
Dive into the research topics of 'Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia'. Together they form a unique fingerprint.